Adjuvants and processes to induce a specific type of immune response
AssigneeBaylor Research Institute
InventorsBali Pulendran, Jacques F. Banchereau, Christopher W. Cutler
Life of this patent
Estimating the term…
Loading patent…
AssigneeBaylor Research Institute
InventorsBali Pulendran, Jacques F. Banchereau, Christopher W. Cutler
Estimating the term…
Porphyromanas gingivalis LPS elicits a Th2 immune response. P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, or mimetics thereof, can be used as adjuvants to elicit a Th2 immune response, increase the efficacy of vaccinations in infectious diseases, decrease the severity of autoimmune responses, boost the Th2 immune response when needed in combination with the Th1 immune response, facilitate the industrial production of antibodies when used in animals, and study the Th2 immune response in laboratory research.
Use of an effective amount of adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof, for the preparation of a pharmaceutical composition for eliciting a Th2 response in a mammal.
Use of an effective amount of an adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof, for the preparation of a pharmaceutical composition for enhancing the immunogenicity of a vaccine in a mammal.
Use of an effective amount of an adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof, for the preparation of a pharmaceutical composition for modulating immunocompetence of a mammal.
Use of an effective amount of an adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof, for the preparation of a pharmaceutical composition for enhancing antibody harvest in a laboratory animal through elicited Th2 immune response.
Use of an effective amount of an adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof, for the preparation of a pharmaceutical composition for treating an autoimmune disease in a mammal.
Use of an effective amount of an adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof, for the preparation of a pharmaceutical composition for treating an infectious disease in a mammal.
Use of an effective amount of an adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof, for the preparation of a pharmaceutical composition for modulating the Th2 immune response in a laboratory animal.
Use of an effective amount of an adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof, for the preparation of a pharmaceutical composition for stimulating IL-5 production in a mammal.
Use of an effective amount of an adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof, for the preparation of a pharmaceutical composition for stimulating IL-13 production in a mammal.
Use of an effective amount of an adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof, for the preparation of a pharmaceutical composition for dampening IFNγ production in a mammal.
A pharmaceutical composition comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
A method of eliciting a Th2 immune response in a mammal comprising administering an adjuvant comprising at least one isolated lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
A method of enhancing the immunogenicity of a vaccine in a mammal comprising co-administering disease-specific antigens and an adjuvant comprising at least one lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
A method of modulating immunocompetence of a mammal comprising administering an adjuvant comprising at least one lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
A method of enhancing antibody harvest in a laboratory animal through elicited Th2 immune response comprising administering to said animal an adjuvant comprising at least one lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
A method for treating autoimmune disease in a mammal comprising administering to said mammal an adjuvant comprising at least one lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
A method for treating an infectious disease in a mammal comprising administering to said mammal an adjuvant comprising at least one lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
A method of modulating the Th2 immune response in a laboratory animal comprising administering to said mammal an adjuvant comprising at least one lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
A method of stimulating IL-5 production in a mammal comprising administering an adjuvant comprising at least one lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
A method of stimulating IL-13 production in a mammal comprising administering an adjuvant comprising at least one lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
A method of dampening IFNγ production in a mammal comprising administering an adjuvant comprising at least one lipid moiety selected from the group consisting of P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, and mimetics thereof.
Dependencies are inferred from the claim text.